目的 在经典方剂四妙勇安汤治疗血栓闭塞性脉管炎确有疗效的前提下，寻找四妙勇安汤治疗血栓闭塞性脉管炎的药效物质基础。方法 以方证代谢组学为研究策略，借助UPLC-MS研究技术，筛选血液代谢生物标记物，在与显效状态的四妙勇安汤血中移行成分建立相关性的前提下，找出四妙勇安汤治疗血栓闭塞性脉管炎的药效物质基础。结果 鉴定出血栓闭塞性脉管炎的30个血液潜在的生物标记物，其中19个代谢标记物在治疗后被四妙勇安汤显著调节；共鉴定出显效状态下68个血中移行成分，其中24个为原型入血成分，44个为代谢成分。结论 通过血清化学成分与代谢标记物关联性分析法分析确定绿原酸、哈巴苷、哈巴俄苷、阿魏酸、甘草苷、甘草酸可能为四妙勇安汤治疗血栓闭塞性脉管炎的药效物质基础。

Objective To explore the pharmacodynamic substance basis of the classic prescription Simiaoyongan Tang (四妙勇安汤, SMYAT) in the treatment of thromboangiitis obliterans (TAO), on the premise that SMYAT is effective in the treatment of TAO. Methods A high-throughput UPLC-MS based on chinmedomics strategy was applied to find out the pharmacodynamic substance basis of SMYAT in the treatment of thromboangiitis obliterans on the premise that the blood metabolic biomarkers filtered established correlation with the blood components of SMYAT in the effective state. Results A total of 30 blood potential biomarkers were identify,19 of which were significantly adjusted by SMYAT; A total of 68 blood components were identify in the effective state, including 24 prototype blood entry components and 44 metabolic ingredients. Conclusion the pharmacodynamic substance basis of SMYAT in the treatment of thromboangiitis obliterans may be chlorogenic acid, harpagide, harpagoside, ferulic acid, liquiritin, glycyrrhizic acid, identified by analysis of plotting of correlation between marker metabolites and serum constituents.

R28

国家自然科学基金重点项目（81830110）;黑龙江省重点研发计划（2022ZX02C04）;黑龙江省中医药管理局青年中医药科研课题（ZHY2023-211）;黑龙江中医药大学校科研基金项目（2024XJJ-QNCX007）;黑龙江中医药大学科研基金项目（2019MS28）